Advanced in Inflammatory Breast Cancer

Sonia Pernas

Avinguda Gran Via 199-203, 
Barcelona, CT, ES 
Advanced in Inflammatory Breast Cancer
Avinguda Gran Via 199-203, 
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Sonia Pernas practices in Barcelona, Spain. Ms. Pernas is rated as an Advanced expert by MediFind in the treatment of Inflammatory Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Mastectomy, and Lymphadenectomy.

Her clinical research consists of co-authoring 97 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Inflammatory Breast Cancer.

Gender
Female

Locations

Avinguda Gran Via 199-203, Barcelona, CT 08908, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)
HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study
A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drug: Atezolizumab+Trastuzumab+Vinorelbine
Study Phase: Phase 2
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Endocrine therapy, Chemotherapy, Antibody-Drug Conjugates
Study Phase: Phase 2
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drugs: Rogaratinib, Palbociclib, Fulvestrant
Study Phase: Phase 1
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Enrollment Status: Unknown
Publish Date: June 23, 2023
Intervention Type: Drug
Study Drug: U3 1402
Study Phase: Early Phase 1
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.
Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.
Enrollment Status: Completed
Publish Date: October 12, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
SOLTI Molecular Screening Program: a Pilot Study to Implement Personalized Therapy for Patients With Advanced or Metastatic Breast Cancer
SOLTI Molecular Screening Program: a Pilot Study to Implement Personalized Therapy for Patients With Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: January 09, 2019
Intervention Type: Procedure
View 7 Less Clinical Trials

97 Total Publications

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial.
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial.
Journal: ESMO open
Published: June 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pernas's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile